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Summary et al. 1994; Papadopoulos et al. 1994), which, in con-
cert, correct single base-pair errors and short mis-
Hereditary nonpolyposis colorectal cancer (HNPCC) is
matched loops (Fishel and Kolodner 1995).
an autosomal dominant disease caused by mutations in
Diagnosis of HNPCC is based on a characteristic fam-
one of at least four different DNA mismatch repair
ily history, the so-called Amsterdam criteria (Vasen et
genes, hMLH1, hMSH2, hPMS1, and hPMS2. Pheno-
al. 1991), and on the identiﬁcation of a mutation in one
typically, HNPCC is characterized by the early onset
of the four mismatch repair genes. Mutations are found
of colorectal cancers and various extracolonic cancers.
mainly in hMLH1 and hMSH2, and, with the exceptions
Depending on the presence or absence of extracolonic
of a frequent mutation in intron 5 of hMSH2 and two
tumors, HNPCC has been divided into two syndromes
Finnish hMLH1 founder mutations in exons 6 and 16,
(Lynch syndrome I and Lynch syndrome II), but, so far,
they are distributed widely among all exons in hMLH1
no correlation to distinct genotypes has been demon-
and hMSH2 (Froggatt et al. 1995; Nystro¨m-Lahti et al.
strated. In this study, we present a frequent hMLH1
1995; Liu et al. 1996). Clinical studies have indicated
intron 14 founder mutation that is associated with a
that HNPCC is a heterogeneous entity (Lynch et al.
highly reduced frequency of extracolonic tumors. The
1988). Depending on the presence of extracolonic tu-
mutation disrupts the splice donor site and silences the
mors, HNPCC may be divided into two syndromes,
mutated allele. Tumors exhibited microsatellite instabil-
which usually are referred to as Lynch syndrome I and
ity, and loss of the wild-type hMLH1 allele was preva-
Lynch syndrome II, but, so far, no distinct genotypes
lent. We propose that the mutation results in a milder
have been assigned to these two phenotypes. Accord-
phenotype, because the mutated hMLH1 protein is pre-
ingly, HNPCC gene carriers cannot be offered individual
vented from exerting a dominant negative effect on the
clinical and prognostic guidelines but are advised to fol-
concerted action of the mismatch repair system.
low the same lifelong clinical surveillance program
aimed at detecting both colonic and extracolonic tu-
Introduction mors.
In this study, we present a frequent hMLH1 intron
Hereditary nonpolyposis colorectal cancer (HNPCC) is
14 splice-donor mutation that is associated with a highly
an autosomal dominant disease characterized by the
reduced frequency of extracolonic tumors. In contrast
early onset of colorectal cancers and a broad spectrum
with other splice-site mutations, this mutation silences
of extracolonic cancers, particularly in the endome-
the affected allele. We propose that the mutation results
trium, the urinary tract, and the small intestine (Watson
in a distinct phenotype, because the mutated hMLH1
and Lynch 1993). HNPCC is caused by mutations in one
protein is prevented from exerting a dominant negative
of at least four different DNA mismatch repair genes,
effect on the concerted action of the mismatch repair
hMLH1, hMSH2, hPMS1, and hPMS2 (Fishel et al.
system.
1993; Leach et al. 1993; Bronner et al. 1994; Nicolaides
Patients, Material, and Methods
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that is, (1) families should exhibit three histologically 1997 by The American Society of Human Genetics. All rights reserved.
0002-9297/97/6101-0019$02.00 veriﬁed cases of colorectal cancer, of which at least one
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should be diagnosed before the patient is 50 years of sequencer and were analyzed with GeneScan Software
2.02 (Applied Biosystems). The frequency of the allelesage; (2) there should be affected individuals in two gen-
erations, and one of these individuals should be a ﬁrst- in the general population was analyzed by the examina-
tion of 36 healthy subjects of Danish origin.degree relative to the other two; and (3) familial adeno-
matous polyposis should be excluded. DNA was avail-
Assessment of Microsatellite Instability (MIN) and Lossable from 21 of the families. Data concerning date of
of Heterozygosity (LOH)birth, date of death, date of operation(s), type(s) of can-
Tissue sections were deparafﬁnized with Histoclearcer(s), and graduation of the cancer(s) are included in
(National Diagnostics) and then with 96% alcohol, afterthe register. Table 1 summarizes the clinical features
which DNA were isolated as described in a previousand the haplotyping of the 9 families with splice-site
study (Strauss et al. 1994). The eight dinucleotide-repeatmutations, compared in this study.
markers that were examined are as follows: D2S123,
DNA and RNA Isolation D2S2156, D3S3512, D3S1611, D3S1298, D5S82,
D5S346, and D17S1881 (Nakamura et al. 1988; SpirioDNA was extracted from whole blood by use of a
et al. 1991; Dib et al. 1996). The oligonucleotides wereQIAamp blood kit or a PureGene DNA isolation kit, in
labeled with ﬂuorescent dyes (6-FAM, TET, and HEXaccordance with the manufacturer’s instructions. RNA
[Applied Biosystems]), and the products were separatedwas isolated from Epstein-Barr virus–immortalized lym-
on an ABI 377 sequencer and were analyzed with Gene-phocytes or from deparafﬁnized tissue sections of nor-
Scan Software 2.02 (Applied Biosystems). A tumor wasmal colon tissue, as described in previous studies (Chirg-
considered to exhibit MIN when allele alterations werewin et al. 1979; Chomczynski and Sacchi 1987).
observed in at least two markers. LOH was calculated
Mutation Analysis as described in a previous study (Canzian et al. 1996).
Mutations in hMLH1 and hMSH2 were examined
by PCR ampliﬁcation of individual exons, followed by Results
direct sequencing. M13-tailed primers covering the ex-
A Frequent hMLH1 Splice-Donor Mutationons and the splice-site junctions were employed, as de-
scribed in previous studies (Kolodner et al. 1994, 1995). In 5 of the 21 Amsterdam-positive families, we de-
tected a splice-donor mutation in intron 14 of hMLH1Direct sequencing of reverse-transcription (RT) PCR
products and genomic PCR products was performed in (ﬁg. 1). The mutation is a combined 7-bp deletion and 4-
bp insertion that leads to the exchange of the obligatoryan ABI 377 DNA sequencer (Applied Biosystems) by
use of dye-terminator or dye-primer cycle sequencing, thymidine at position /2 and to the exchange of con-
served purines at positions /3 to /5, in the splice donoraccording to the manufacturer’s manual. All mutations
were conﬁrmed by analysis of two independently col- site. Following ampliﬁcation of a 1,219-bp cDNA frag-
ment encompassing exons 11–19, only the wild-typelected blood samples and were sequenced in both direc-
tions. hMLH1 RNA was ampliﬁed by RT-PCR. cDNA allele was detected (ﬁg. 2A). Sequencing of the RT-PCR
product from both lymphocytes and normal colon tissuewas generated by use of random hexamers and 1 mg
total RNA template. Ampliﬁcation of a 1,220-nucleo- showed that the cDNA exhibited the normal splice junc-
tion from exon 14 to exon 15. In order to conﬁrm thattide hMLH1 cDNA fragment extending from position
036 upstream of the AUG codon to codon 394 was the mutated allele was not expressed, we examined the
relative expression of an ArG isoleucine 219–to-valineperformed with primers 5-GCATCTAGACGTTTC-
CTTGGC-3 and 5-CATCAAGCTTCTGTTCCCG-3. polymorphism in exon 8 of hMLH1 (ﬁg. 2B) (Tan-
nerga˚rd et al. 1995). Whereas the two alleles were de-Ampliﬁcation of 1,219 base pairs covering codons 326–
731 was performed with primers 5-GGGGTGCAG- tected in DNA, the A allele was almost completely unde-
tectable in RNA. Since the A allele segregated with theCAGCACATCG-3 and 5-GGAGGCAGAATGTGT-
GAGCG-3. intron 14 mutation (see table 2), we conclude that the
mutation silences the allele.
Haplotyping Two other families exhibiting a previously character-
ized ArT splice-donor mutation at position/3 of intronHaplotyping was performed with microsatellites
D2S2378, D2S2156, D2S2369, D2S2316, D2S123, 5 in hMSH2 (Liu et al. 1994; Froggatt et al. 1995) and
two families with an hMLH1 ArT mutation at positionD2S2292, D2S2251, D3S1283, D3S1266, D3S1609,
D3S3512, D3S1611, D3S1298, and D3S3521 (Dib et al. 02, relative to the 3 splice site, in intron 15 (Wijnen et
al. 1996) also were detected among the Amsterdam-1996). The marker sets were intragenic or were ﬂanking
hMSH2 or hMLH1, spanning 6.5 cM or 11.2 cM, re- positive families. In contrast with the intron 14 muta-
tion, the mutated alleles were expressed. The hMLH1spectively. The products were separated on an ABI 377
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Table 1
Clinical Features of the Affected Individuals in the Amsterdam-Positive Families
with Splice-Site Mutations
Location of
No. of Age(s) at Extracolonic Cancer(s) Haplotype
Mutation and Colorectal Surgery (Age[s] at Diagnosis, Analysis
Family-Individual Cancers (Years) in Years) Performed
hMLH1 intron 14:
12-02 1 . . .
12-04 1 37
12-08 2 37, 37
12-14 1 40
12-16 2 35, 39 X
18-06 1 74
18-08 1 31
18-10 1 37
18-14 1 39
18-22 1 56
18-26 1 31 X
21-02 1 . . .
21-06 2 50, 53 X
21-08 1 33 X
21-12 1 45
21-16 3 49, 51, 58 Endometrium (33)
21-26 4 55, 61, 64, 65 Ampulla of vater (54)
21-32 1 37 X
31-02 2 55, 66
31-04 1 57 X
31-10 1 33 X
41-04 1 . . .a
41-08 1 48
41-10 2 42, 42
41-20 2 33, 33 X
hMLH1 intron 15 or
hMSH2 intron 5:
3-06 4 33, 39, 41, 51 Jejunum (29)
3-08 2 40, 50 Bladder (51)
3-16 1 25 X
5-06 . . . . . . Small intestine (37)
5-12 1 57
5-20 3 47, 52, 55 Jejunum (56) X
5-22 3 37, 42, 48 Endometrium (45)
5-26 1 33
5-28 1 51
5-32 1 37 X
5-38 2 32, 32 X
42-02 3 37, 52, 55 Urinary tract (69, 69)
42-06 . . . . . . Pancreas (48)
42-12 1 46
42-14 1 27 X
111-02 1 52 Lower limb X
(Osteosarcoma) (80)
111-04 2 56
111-34 1 55 Endometrium (53)
111-50 . . . . . . Ovary, ileum (36, 45)
111-54 1 13
111-56 1 42
NOTE.—All persons are proven gene carriers or obligate gene carriers, since they have passed the gene
to their children. Furthermore, 20 nonaffected individuals and 3 spouses, from the families, were haplotyped.
a Patient died at age 52 years.
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Figure 1 Sequence of the frequent hMLH1 splice-site mutation.
Exon 14 in hMLH1 was ampliﬁed from genomic DNA and was se-
quenced. Top, Electropherogram of the splice-donor mutation. Bot-
tom, Sequence of the wild-type and mutant alleles.
intron 15 mutation leads to a so-called in-frame deletion
of exon 16, and the hMSH2 intron 5 mutation leads to
an in-frame deletion of exon 5, in the mature transcript
(Liu et al. 1994; Froggatt et al. 1995; Wijnen et al.
1996).
Haplotyping
Genealogical data showed that the families with the
hMLH1 intron 14 mutation and the families with the
hMLH1 intron 15 mutation were unrelated within the
last four generations. Around the turn of the century,
however, they lived within relatively narrow geo-
graphic areas, on the Island of Sealand and in a munici-
pality in northern Jutland (ﬁg. 3). Haplotyping, with
Figure 2 Silencing of the hMLH1 intron 14 mutant allele. A,ﬁve markers spanning a total of ú7.4 cM, of the fami-
RT-PCR analysis of mRNA from an hMLH1 intron 14 mutationlies exhibiting the hMLH1 intron 14 mutation showed
carrier (lane 2) and a normal subject (lane 4) are shown. Control
that the diseased gene segregated with the same haplo- samples in which RT was omitted are shown (lanes 1 and 3).
type in all affected individuals (n Å 8; table 2) and cDNA was ampliﬁed with primers, generating a 1,219-bp fragment
encompassing the region from codon 326 in exon 11 to codonin two gene carriers, indicating that the families were
731 in exon 19 and was examined by agarose-gel electrophoresis.related. The haplotype comprised the intragenic
The electropherogram shows the normal splice junction from exonD3S1611 marker and the three ﬂanking markers
14 to exon 15, in the cDNA fragment. B, Sequence of exon 8 in
D3S1609, D3S3512, and D3S1298. Analysis of the hMLH1, in DNA (top) and RNA (bottom). DNA was ampliﬁed
ArG isoleucine 219–to-valine polymorphism in exon with intron primers, as described in Patients, Material, and Meth-
ods, and cDNA was generated with primers extending from posi-8 (Tannerga˚rd et al. 1995) showed that the mutated
tion 036 upstream from the AUG codon to codon 394. The PCRallele segregated with isoleucine, in all families. When
products were sequenced with ﬂuorescent-dye terminators. Thehaplotyping was extended to span a total of ú11.2 cM,
position of the exon 8 ArG polymorphism is indicated by an
by application of two additional telomeric markers, asterisk (*).
D3S1283 and D3S1266, and of one centromeric
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Table 2
Haplotypes of Affected Individuals from Families with hMLH1 and hMSH2 Mutations
HAPLOTYPE
OF hMLH1
INTRON 15– FREQUENCY OF
HAPLOTYPE OF hMLH1 INTRON FREQUENCY OF MUTATION FOUNDER
14–MUTATION FAMILYb FOUNDER ALLELESc FAMILYb ALLELESc
MARKER/ DISTANCE
EXONa (cM) 12 21 31 18 41 Danish CEPH 3 5 Danish CEPH
D3S1283  .1 
158 158 158 158 158 .30 .34 158 158 .30 .34
D3S1266  2.6 
297 297 297 293 293 .17/.25d .14/.19d 289 289 .29 .26
D3S1609  6.8 
257 257 257 257 257 .33 .34 253 253 .60 .48
D3S3512  .0 
133 133 133 133 133 .35 .52 141 141 .04 .13
Exon 8e  .0 
A A A A A .69 . . . . . . . . . . . . . . .
D3S1611  .6 
268 268 268 268 268 .03 .05 252 252 .20 .21
D3S1298  1.1 
210 210 210 210 210 .09 .11 . . . . . . . . . . . .
D3S3521 269 269 269 279 279 .03/.19d .06/.19d 281 281 .34 .29
HAPLOTYPE OF hMSH2 INTRON 5–MUTATION FAMILYb
42 111f
D2S2378  3.3 
203 198, 208
D2S2156  .0 
169 171, 171
D2S2369  .0 
256 250, 250
D2S2316  .0 
122 116, 126
D2S123  2.7 
213 213, 217
D2S2292  .5 
284 262, 262
D2S2251 282 280, 288
a Markers are listed in order.
b Haplotypes with preserved alleles are within the unshaded region, and haplotypes with distinct alleles are within the shaded region.
c Determined from analysis of 72 chromosomes from 36 Danish controls and of 56 CEPH chromosomes.
d The ﬁrst frequency is for the allele shared by families 12, 21, and 31, and the second frequency is for the allele shared by families 18
and 41.
e The nucleotide at polymorphic site 219 is indicated.
f Haplotype of each allele is shown, since it was not possible to determine which haplotype segregated with the mutation.
marker, D3S3521, two recombination events resulting Extracolonic Cancers in HNPCC Kindreds
in two different haplotypes were apparent, in three and A comparison of the tumor spectrum of the 28 Am-
in two of the families. The gene frequencies also were sterdam-positive families from the Danish HNPCC reg-
determined in 36 unrelated controls (table 2). The like- ister with that of the general population showed, in
lihood of ﬁnding, by chance, one of the two different agreement with the results of previous studies, that
haplotypes in a non–gene carrier was found to be 3.3 HNPCC families frequently acquire tumors in the endo-
1 1007 for one haplotype and 3.1 1 1006 for the other. metrium and the urinary tract, in addition to colorectal
When the ﬁve markers shared by all families were con- cancer (ﬁg. 4) (Vasen et al. 1990; Watson and Lynch
sidered, the likelihood was 2.2 1 1004. The two fami- 1993). HNPCC generally is considered to be heteroge-
lies with the hMLH1 intron 15 mutation exhibited an neous, since certain HNPCC families exhibit few extra-
identical haplotype over the examined 11.2-cM DNA colonic tumors. We therefore compared the frequency
strand containing hMLH1. The likelihood of this hap- of extracolonic cancers in the ﬁve families with the in-
lotype was 1.4 1 1004. In the two families (42 and tron 14 founder mutation with that of the other Amster-
111) with hMSH2 intron 5 mutations, the haplotype dam-positive families in the register (table 3). The me-
segregating with the mutated allele was known only in dian age for diagnosis of the ﬁrst colorectal cancer was
family 42. However, the two families differed in 13 of comparable in the two groups. However, since only 2
14 possible alleles, and it could therefore be concluded of 25 affected individuals suffered from an extracolonic
cancer, the affected individuals in the families with thethat they were unrelated.
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Figure 3 Pedigrees and origins of Danish families with either hMLH1 intron 14 or hMLH1 intron 15 founder mutations
intron 14 mutation were found to have signiﬁcantly maining markers were located at the hMSH2 (D2S123
and D2S2156), APC (D5S82 and D5S346), and p53fewer extracolonic tumors (P õ .05) than those in the
Amsterdam-positive families. The ﬁrst patient had endo- (D17S1881) loci (ﬁg. 5). All tumors exhibited MIN in
more than four of the markers. LOH at the hMLH1metrial cancer, by the age of 33 years, and three succes-
sive colorectal cancers, and the second patient had can- locus, deﬁned as a ú40% signal reduction of one allele
(Canzian et al. 1996), was observed in three tumors. Incer of the ampulla of vater, by the age of 54 years, and
four colorectal cancers. In the four families with the all cases, the loss occurred in the hMLH1 wild-type
allele. In the remaining four tumors, LOH could nothMLH1 intron 15 and hMSH2 intron 5 splice-site muta-
tions, almost 50% of the affected individuals had extra- be determined, owing to the occurrence of MIN. We
conclude that the founder mutation is associated withcolonic tumors. This frequency not only was signiﬁ-
cantly higher (P õ .01) than that found in families with MIN and that loss of the wild-type hMLH1 allele is a
frequent event in the tumors.the intron 14 mutation, but it also was higher (P õ .05)
than that found in the collection of Amsterdam-positive
families. Discussion
MIN and LOH In this study, we demonstrate a frequent founder muta-
tion in hMLH1, which leads to an attenuated HNPCCMIN and LOH at the hMLH1 locus were examined
with eight microsatellite markers, in seven parafﬁn-em- phenotype characterized by a highly reduced frequency of
extracolonic tumors. The hMLH1 intron 14 mutation wasbedded colorectal tumors from four of the founder fami-
lies. Three markers were located at the hMLH1 locus found in Ç25% of the Danish Amsterdam-positive
HNPCC kindreds and was localized to the splice donor site(D3S3512, D3S1611, and D3S1298), whereas the re-
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Figure 4 Distribution and frequency of extracolonic cancers in HNPCC patients. Proportional distribution of extracolonic cancers in
different organ systems in females and males from HNPCC families and in the Danish population of 1993 (Storm et al. 1993). The HNPCC
material included 36 neoplasms collected over the period 1910–1996. The grouping called ‘‘Other speciﬁed’’ included tumors in the eye and
lachrymal glands, brain and nervous system, thyroid, endocrine glands, and bone and connective tissue.
of intron 14. Basically, the mutation is a combined 4-bp splice junction are changed. In contrast with other splice-
site mutations that result in exon skipping, intron retention,substitution and 3-bp deletion, in which the ﬁrst four nucle-
otides are complementary to the wild-type sequence. In this or use of cryptic donor/acceptor sites, the hMLH1 intron
14 splice-donor mutation silences the mutant allele. Down-way, ﬁve of the six highly conserved nucleotides in the
Table 3
Frequency of Extracolonic Tumors in Affected Individuals with the hMLH1 Intron 14 Mutation,
Compared with the Remaining Amsterdam-Positive Families of the HNPCC Register and
with Affected Individuals with an hMLH1 Intron 15 or an hMSH2 Intron 5 Mutation
Families with
Families with hMLH1 Intron 15 Amsterdam-
hMLH1 Intron 14 or hMSH2 Intron 5 Positive
Splice-Site Mutations Splice-Site Mutations Families
Median age (range) at ﬁrst
colorectal cancer diagnosis
[years] 39 (31–74) 38 (14–58) 42 (14–81)
No. of individuals with colorectal
cancer 23 11 80
No. of individuals with colorectal
and extracolonic cancer or
extracolonic cancer only 2a 10b,c 34
NOTE.—Affected individuals are deﬁned as gene carriers or as obligate gene carriers. The number of
extracolonic cancers in the different groups were compared by use of Fisher’s exact test.
a Comparison of the hMLH1 intron 14–mutation families with the Amsterdam-positive families resulted
in P õ .05.
b Comparison of the hMLH1 intron 14–mutation families with the hMLH1 intron 15– and the hMSH2
intron 5–mutation families resulted in P õ .01.
c Comparison of the hMLH1 intron 15– and the hMSH2 intron 5–mutation families with the Amsterdam-
positive families resulted in P õ .05.
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Figure 5 MIN and LOH in colorectal tumors from founder families. A, Analysis of locus D3S1611, in leukocytes (top panel) and in
tumor tissue (bottom panel), from patient 41-20. The x-axis indicates the size of the alleles, in bp, and the y-axis indicates the peak heights,
in ﬂuorescence units. The positions of the two alleles are indicated by the blackened trace. B, Assessment of LOH in locus D3S1611, in tumor
tissue from patient 12-16. The wild-type and mutant alleles in normal leukocytes (top panel) and the alleles in tumor tissue (bottom panel) are
shown. LOH was deﬁned as a ú40% reduction in the relative intensity of the wild-type allele and was calculated by use of the formula L Å
(aT2 1 aN1) / (aT1 1 aN2), where a is the area of the peaks (Canzian et al. 1996). When L ú 1.67, the allele is decreased ú40%. In this case,
L was 1.92.
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regulation of the mutant allele by defective splice junctions hMSH2 mutations and found no difference between the
two groups. Since efﬁcient mismatch repair requires themay be accomplished by retention of the pre-mRNA in
incomplete spliceosomes (Legrain and Rosbach 1989) or by concerted action of hMSH2, hMLH1, hPMS2, and hMSH6
(Fishel and Kolodner 1995), distinct phenotypes may notnonsense codon–directed mRNA degradation, as described
in previous studies (Maquat 1995; Aoufouchi et al. 1996). depend on whether mutations are found in hMSH2 or in
hMLH1. Two different disease-modifying mechanisms,In agreementwith the unusual composition of the mutation,
haplotyping shows that all affected kindreds are related. which would operate independently of the involved gene,
may be envisaged. The ﬁrst involves the presence of a linkedWe have not determined when the intron 14 mutation origi-
nated, but, in a recent study, Moisio et al. (1996) were able modiﬁer gene, within 7.4 cM of hMLH1, that could com-
pensate for defective DNA repair, in a tissue-speciﬁc man-to determine that the origin of a Finnish founder mutation
was during the 16th century. In the Finnish kindreds, a ner. The second model implies a dosage effect. Rather, we
propose that it is the silencing of the mutated allele that isdistinct haplotype spanning Ç12 cM, comprising markers
similar to those employed in this study, was preserved with- responsible for the milder phenotype, because the mutated
hMLH1 protein is prevented from exerting a dominantout recombinations. In view of the fact that the haplotype
in the Danish kindreds was preserved only within 7.4 cM negative effect on the mismatch repair system. One other
hMLH1 mutation associated with allelic inactivation hasand that two recombination events were observed within
markers spanning 11.2 cM, it is likely that the Danish been reported by Liu et al. (1996), unfortunately without
reference to extracolonic manifestations. In agreement withfounder mutation is older than the Finnish mutation. The
two kindreds sharing the hMLH1 intron 15 splice-acceptor such a model, the families with the hMSH2 intron 5 or the
hMLH1 intron 15 splice-site mutations, which result inmutation came from the same conﬁned geographical area
and therefore, not surprisingly, also were related. In con- the expression of a defective protein, all exhibited a high
frequency of extracolonic tumors, corresponding to Lynchtrast, the families exhibiting the frequent hMSH2 intron 5
splice-site mutation clearly were unrelated, as demonstrated syndrome II. The number of extracolonic cancers was sig-
niﬁcantly higher than in the complete collection of Amster-in a previous study (Froggatt et al. 1995). It is striking
that this mutation is located in connection to 26 successive dam-positive families, which is in agreement with the obser-
vation that Amsterdam-positive families represent a mixtureadenosine residues, which have a strong potential for stack-
ing. During replication, the polymerase is likely to slide on of families with low, as well as high, frequencies of extraco-
lonic cancers.the DNA strand, and, therefore, this site may be subject to
frequent mutations. In conclusion, we present a frequent hMLH1 founder
mutation that phenotypically corresponds to Lynch syn-The collection of Amsterdam-positive families in theDan-
ish HNPCC register demonstrates that Ç30% of the af- drome I. Although additional studies of kindreds with other
inactivating mutations are needed, the results imply thatfected individuals in HNPCC families develop an extraco-
lonic cancer. In agreement with the results of previous clinical surveillance could be restricted to colonic examina-
tions in HNPCC gene carriers with monoallelic hMLH1studies (Vasen et al. 1990; Watson and Lynch 1993), extra-
colonic tumors were found mainly in the urinary tract and expression.
the endometrium, which clearly is distinct from the general
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